In contrast, another meta-analysis33found no association between GLP-1 receptor agonists (including liraglutide and semaglutide) and DVT risk (2/5,015 vs. 3/2,237; RR 0.30, 95% CI 0.06–1.40), although this study focused on patients with obesity or overweight conditions.81, 82, 83, 84. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.